CORT
Corcept Therapeutics Incorporated
NASDAQ: CORT · HEALTHCARE · BIOTECHNOLOGY
$51.20
-3.03% today
Updated 2026-06-05
Market cap
$8.90B
P/E ratio
236.89
P/S ratio
11.57x
EPS (TTM)
$0.35
Dividend yield
—
52W range
$29 – $91
Volume
1.2M
WallStSmart proprietary scores
37
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
4.7
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$70.83
+38.34%
12-Month target
$24.55
-52.05%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.68 — safe zone
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Negative free cash flow $-16.97M
- P/E 236.89x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $401.86M | $482.38M | $675.04M | $761.41M | $769.10M | $1.0B |
| Net income | $101.42M | $106.14M | $139.73M | $99.65M | $-31.20M | — |
| EPS | — | — | — | — | $0.35 | $0.68 |
| Free cash flow | $119.91M | $126.90M | $195.90M | $141.78M | $-16.97M | — |
| Profit margin | 25.24% | 22.00% | 20.70% | 13.09% | 6.16% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-02 | ROBB, GARY CHARLES | Sale | 358 | $70.44 |
| 2026-06-02 | MOKARI, ATABAK | Sale | 395 | $70.44 |
| 2026-06-02 | MADUCK, SEAN | Sale | 452 | $70.44 |
Peer comparison
Smart narrative
Corcept Therapeutics Incorporated trades at $51.20. representing a P/E of 236.89x trailing earnings. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 4.68, it sits in the safe zone. TTM revenue stands at $769.10M. with profit margins at 6.16%.
Frequently asked questions
What is Corcept Therapeutics Incorporated's stock price?
Corcept Therapeutics Incorporated (CORT) trades at $51.20, on a P/E of 236.9x and a P/S of 11.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Corcept Therapeutics Incorporated overvalued?
Corcept Therapeutics Incorporated carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Corcept Therapeutics Incorporated (CORT)?
The 12-month analyst consensus target is $70.83, about 38.3% above the current $51.20. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of CORT by 2030?
Our research-backed model puts the 2030 base case at $76.50, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Corcept Therapeutics Incorporated's revenue?
Corcept Therapeutics Incorporated's trailing twelve-month revenue is $769.10M, and our model projects it reaching about $1.78B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Corcept Therapeutics Incorporated's Altman Z-Score is 4.68, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio11.57x
ROE7.51%
Beta0.50
50D MA$55.70
200D MA$59.72
Shares out0.11B
Float0.09B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—